Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy.

Abstract

Cancer immunotherapy often fails to result in a favorable outcome owing to poor activation of immune response, the immunosuppressive tumor microenvironment, and systemic toxicity. In this study, indocyanine green (ICG) was conjugated with doxorubicin (DOX) using a hydrazone linker (DOX-ICG). Results of our in vitro and in vivo studies indicated that DOX-ICG could trigger powerful immunogenic cell death (ICD) of tumor cells. Moreover, its use in combination with immune checkpoint inhibitors could effectively inhibit both primary and abscopal tumors growth and suppress tumor metastasis. Therefore, this simple, safe, and efficient prodrug shows great potential for use in photo-activated chemo-immunotherapy.

• Authors: Chan Jin, Yan Wang, Yanfeng Li, Jinbo Li, Shuang Zhou, Jiang Yu, Zhaomeng Wang, Yueyang Yu, Haotian Zhang, Dun Wang, Zhonggui He, Yongjun Wang
• Journal: International journal of pharmaceutics (Int J Pharm) Vol. 607 Pg. 121027 (Sep 25 2021) ISSN: 1873-3476 [Electronic] Netherlands
• PMID: 34418473 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Doxorubicin
• Indocyanine Green

Topics

• Cell Line, Tumor
• Doxorubicin
• Humans
• Immunogenic Cell Death
• Immunotherapy
• Indocyanine Green
• Neoplasms (drug therapy)
• Tumor Microenvironment